2. Academic Validation
  3. Design and synthesis of the tumor-activated prodrug of dihydropyrimidine dehydrogenase (DPD) inhibitor, RO0094889 for combination therapy with capecitabine

Design and synthesis of the tumor-activated prodrug of dihydropyrimidine dehydrogenase (DPD) inhibitor, RO0094889 for combination therapy with capecitabine

  • Bioorg Med Chem Lett. 2003 Mar 10;13(5):867-72. doi: 10.1016/s0960-894x(02)01082-x.
Kazuo Hattori 1,  Yasunori Kohchi,  Nobuhiro Oikawa,  Hitomi Suda,  Masako Ura,  Tohru Ishikawa,  Masanori Miwa,  Mika Endoh,  Hiroyuki Eda,  Hiromi Tanimura,  Akira Kawashima,  Ikuo Horii,  Hideo Ishitsuka,  Nobuo Shimma
Affiliations

Affiliation

  • 1 Department of Chemistry, Nippon Roche Research Center, 200 Kajiwara, Kamakura, Kanagawa 247-8530, Japan.
PMID: 12617910 DOI: 10.1016/s0960-894x(02)01082-x
Abstract

A series of tumor-activated prodrugs of the inhibitors of dihydropyrimidine dehydrogenase (DPD), an enzyme catabolizing 5-fluorouracil (5-FU: 4g), has been designed and synthesized. RO0094889 (11c) is a prodrug of 5-vinyluracil (4c), a known DPD inhibitor, and was designed to generate 4c selectively in tumor tissues by sequential conversion of 11c by three enzymes: esterase, cytidine deaminase and thymidine Phosphorylase, the latter two of which are known to be highly expressed in various tumor tissues. When capecitabine (1), a tumor-activated prodrug of 5-FU, was co-administered orally with 11c, 5-FU in tumor tissues was significantly increased with only a slight increase of 5-FU in plasma as compared with oral capecitabine alone.

Figures
Products